CAMBRIDGE, Mass. (Feb 7, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the 2017 BIO CEO & Investor Conference on Monday, February 13, 2017 at 11:30 A.M. Eastern Time at the Waldorf Astoria in New York, NY. Mr. Perrin will highlight the recent progress of the Company’s Neuro-Spinal Scaffold™ program, and provide an overview of the Company.
A live webcast will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2017/56115496336.cfm and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in approximately 5-10 minutes before the event to ensure a timely connection.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies and will take place at the Waldorf Astoria February 13 – 14, 2017.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.